NOS-IN-2 (Compound 4i), an imidamide-derived NOS inhibitor, exhibits high potency and selectivity, specifically inhibiting iNOS with an IC50 of 20 μM while sparing eNOS. Demonstrating minimal toxicity, it is suitable for research on inflammatory disorders [1].

NOS-IN-2 (Compound 4i) exhibits high iNOS selectivity with no eNOS inhibition activity [1] and demonstrates minimal toxicity (0-100 μM, 30 min) [1]. In a Cell Viability Assay using HUVECs, little toxicity was observed except at concentrations above 100 μM, where cell viability was significantly reduced by approximately 20% [1].

NOS-IN-2 (Compound 4i) is anticipated to exhibit oral bioavailability [1].